The Supplement consists of one Editorial, three Commentaries and eleven Research Reports.
The objectivity of the articles differs substantially; one of the Commentaries could be classified as puffery and elements of the Editorial are on the edge. CRE has not reviewed the Research Reports in detail, but CRE has reviewed the most significant initiation/cessation studies identified by FDA.